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HIV-1 Tat protein regulates viral gene expression by modulating the activity and association of cellular transcription factors
with RNA polymerase II (RNAPII). Possible mechanisms include Tat-associated protein kinase(s) and phosphatase(s) that
regulate phosphorylation of the C-terminal domain (CTD) of the large subunit of RNAPII. Hypophosphorylated RNAPII
(RNAPIIa) is recruited to promoters during formation of a preinitiation complex, whereas hyperphosphorylated RNAPII
(RNAPIIo) is associated with the elongation complex. The role of phosphatases in maintaining the equilibrium between the
two phosphorylated states of RNAPII, which is required for sustained transcriptional activation from the HIV-1 LTR, is not
clear. In this study, we discuss the properties of a Tat-associated CTD phosphatase fractionated from Jurkat T cells. The
Tat-associated protein phosphatase (TAPP) is related to the serine/threonine, type 1, protein phosphatase (PP1) family. TAPP
dephosphorylates the hyperphosphorylated form of recombinant CTD specifically on serine 2, and augments Tat-mediated
transcriptional transactivation of HIV-1 LTR in an in vitro transcription reaction. TAPP is associated with the transcription
complex during the early initiation steps, and its release from the HIV-1 promoter coincides with the Tat-specific activation
of CDK9. The results suggest a unique role of the Tat-associated phosphatase which regulates viral transcription byINTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) regula-
tory protein Tat functions as a transcriptional transacti-
vator to increase the production of full-length viral tran-
scripts (Boris-Lawrie et al., 1992; reviewed by Karn, 1999;
Cullen, 1998; and Taube et al., 1999). Tat specifically
recognizes the pyrimidine bulge region of the transacti-
vation-response (TAR) RNA element present at the 5-
untranslated region of viral transcripts (Churcher et al.,
1993; Rounsville et al., 1996). However, Tat transactiva-
tion of the HIV-1 promoter requires specific interaction
with the host cell Tat cofactors. HIV-1 Tat has been
shown to bind to general transcription factors (GTFs)
such as Sp1, RNA polymerase, TATA-binding protein
(TBP)-associated TFIID, and T-cell-derived Tat-associ-
ated CTD kinase (TTK) (Jeang et al., 1993; Mavankal et
al., 1996; Kashanchi et al., 1994; Nekhai et al., 1997, 2000).
Specifically, HIV-1 Tat stimulates transcription elongation
by binding to the CDK9/cyclin T1 (P-TEFb) complex (Wei
et al., 1998). The binding of cyclin T1 to Tat and the
formation of the tripartite complex among Tat, cyclin T1,
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6and TAR depends on the pyrimidine bulge and the loop
domains in TAR, and is markedly induced by CDK9 au-
tophosphorylation (Wei et al., 1998; Garber et al., 1998,
2000; Bieniasz et al., 1998). The recruitment of P-TEFb to
the HIV-1 promoter complex is necessary and sufficient
to promote transcriptional elongation and the target-
specific phosphorylation of RNA polymerase II (RNAPII)
CTD repeats (Garber et al., 2000; Zhou et al., 2000, 2001).
However, the mechanism by which target-specific phos-
phorylation of the CTD residues is regulated during tran-
scriptional elongation remains unclear.
It has been suggested that HIV-1 Tat tethers RNAPII
regulatory factors to the transcription complex in order to
sustain processive transcription from viral LTR (Karn,
1999). A unique characteristic of eukaryotic RNAPII is the
presence of multiple repeats of a consensus heptad
sequence, Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (52 repeats
in mammalian cells and 26–27 repeats in yeast), at the
C-terminus of its largest subunit (for review, see Corden,
1990). The C-terminal domain consists of over 250
serine, threonine, and tyrosine residues, with serine be-
ing the major site of phosphorylation (Dahmus, 1996).
The phosphorylated state of CTD is correlated with the
elongation efficiency of the RNAPII enzyme complex
(Dahmus, 1995).target-specific dephosphorylation of RNAPII during the ear
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A number of studies have proposed CTD hyperphos-
phorylation as one of the major regulatory mechanismsly stag
phosp
by which Tat enhances elongation of viral transcripts
from the HIV-1 LTR. Several protein kinases such as
TFIIH-associated CDK7, CDK9/cyclin T1 (TAK), and TTK
have been shown to phosphorylate the RNAPII CTD and,
thus, may play a regulatory role in the viral transcriptional
elongation mechanisms (Feaver et al., 1991; Jones, 1997;
Wei et al., 1998; Bensaude et al., 1999; Nekhai et al.,
1997). The Tat-associated kinase TAK contains CDK9
(Zhu et al., 1997), which is homologous to P-TEFb, a
positive transcription elongation factor originally identi-
fied in Drosophila (Marshall and Price, 1995). Importantly,
CDK9 autophosphorylation promotes binding of the Tat/
P-TEFb complex to TAR RNA; interestingly the CDK9
autophosphorylation appears to be independent of Tat
(Fu et al., 1999; Garber et al., 2000; Price, 2000).
While a protein phosphatase that dephosphorylates
the hyperphosphorylated form of RNAPII CTD has been
described (Chambers and Dahmus, 1994), the role of
protein dephosphorylation in transcriptional transactiva-
tion is less clear. Chambers and Dahmus reported a
negative effect of CTD phosphatase on HIV-1 transcrip-
tion. However, a clearer understanding of the specific
targets of serine/threonine phosphatases and the role
they play in the transcription process is incomplete.
The CTD phosphatase, identified by Dahmus and col-
leagues, was stimulated by the RAP74 subunit of TFIIF.
Interestingly, TFIIB inhibited stimulation of the CTD phos-
phatase (Chambers et al., 1995). The TFIIF-associated
CTD phosphatase contains a catalytic subunit referred to
as FCP1 (Marshall et al., 1998). FCP1 recycles phosphor-
ylated RNAPIIo to underphosphorylated RNAPIIa (Cho et
al., 1999). These studies, however, did not address if the
phosphatase dephosphorylated specific residues of
CTDo, and importantly, whether such a phosphatase
regulates Tat transactivation of the HIV-1 promoter.
Here, we report the characterization of a Tat-associated
protein phosphatase (TAPP), from Human T cells. TAPP is a
serine/threonine type 1 protein phosphatase (PP1) that spe-
cifically dephosphorylates serine 2 residues of the CTD in
RNAPII. In vitro transcription studies show that TAPP aug-
ments Tat-mediated transcriptional transactivation from the
HIV-1 LTR, but not from the HTLV-1 promoter. Furthermore,
we demonstrate that PP1 is associated with the preinitia-
tion complex (PIC) and exits the transcription complex as
elongation progresses.
RESULTS
Purification of TAPP from human T lymphocytes
We utilized transcriptionally active Jurkat T-cell ex-
tracts as the source of Tat-associated phosphatase. Fig-
ure 1 shows the scheme for partial purification of TAPP
using the initial 0–40% ammonium sulfate precipitate
fraction. Ammonium sulfate fraction, AS Fr. I, containing
the TAPP activity was further fractionated by High Q
column chromatography as described under Materials
and Methods. A general substrate for protein phospha-
tases, phosphorylase a, was used to test for TAPP activ-
ity (Shenolikar and Nairn, 1991). Commercially available
PP1c purified from rabbit skeletal muscle (rPP1c) was
used as a positive control for phosphatase activity. The
next phase of the fractionation was to determine the Tat
affinity of the AS Fr. I (Fig. 1). The AS Fr. II did not contain
Tat-associated protein phosphatase activity and was not
pursued. To determine whether the phosphatase fraction
associated with specific Tat domains, we compared the
activities of TAPP fractions that bind to Tat48, which
contains the N-terminal activation domain of Tat and the
full-length Tat72. Phosphatase activity associated with
the N-terminal domain of Tat, as well as the full-length
Tat1–72 (Fig. 2A, lanes 3 and 5). Ammonium sulfate
fraction II (AS Fr. II) contained no TAPP activity (lanes 2
and 4).
The specificity of TAPP was further analyzed by mea-
suring the phosphatase activity of proteins associated
with another viral transactivator, VP16. The herpes sim-
plex virus transcriptional transactivator analogous to
HIV-1 Tat, VP16, stimulates gene expression during virus
infection (Tal-Singer et al., 1999). No phosphatase activity
was associated with GST-VP16 fusion protein above the
background level activity associated with GST beads
alone (Fig. 2B).
TAPP is a type 1 serine/threonine protein
phosphatase
Next, we asked what type of phosphatase activity was
associated with TAPP. Specific phosphatase inhibitors
FIG. 1. Purification of Tat-associated protein phosphatase(s) by ammo-
nium sulfate precipitation and Tat affinity chromatography. TAPP from
Jurkat whole cell extracts (WCE) was purified as shown in the flowchart.
WCE was partially purified using ammonium sulfate (AS or ASO4); super-
natant (sup), precipitate (ppt). AS Fraction [Fr.] I contained (0–40% ASO4)
while AS Fraction [Fr.] II (40–100% ASO4). AS Fr. I was further purified on
a High Q chromatographic column. The peak phosphatase fraction was
placed on a GST-Tat affinity column andwashedwith 50mMManley buffer
to obtain the Tat-associated protein phosphatase (TAPP).
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were used to differentiate between different types of
protein phosphatases. Figure 3A shows dephosphoryla-
tion of phosphorylase a substrate by GST-Tat-TAPP in the
presence or absence of specific phosphatase inhibitors:
microcystin (MC, inhibits both protein phosphatase 1 and
2A) and okadaic acid (OA, inhibits PP1 at 200 nM and
PP2A at 1.0 nM) (Hamm-Alvarez et al., 1996). Ten nano-
molar microcystein inhibits TAPP, rPP1c, and rPP2Ac
(Fig. 3A, top panel) and is thus insufficient to discriminate
between different types of phosphatases. Okadaic acid
at 200 nM inhibited TAPP and rPP1c, while 1.0 nM OA
inhibited rPP2Ac (Fig. 3A, bottom panel). OA at 1.0 nM
concentration did not inhibit TAPP, suggesting that it is
not a type 2A phosphatase (Fig. 3B, lane 3). Both micro-
cystin (10 nM) and OA (200 nM) inhibited TAPP, suggest-
ing that TAPP is a type 1 serine/threonine protein phos-
phatase (Fig. 3B, lanes 2 and 4).
To establish the presence of PP1 in the TAPP fraction,
Western blot analysis using the anti-PP1c and anti-
PP2Ac antibodies was performed on fractions collected
throughout the purification scheme. Whole cell extract,
AS Fr. I, and AS Fr. II contained the catalytic subunits of
PP1 and PP2A (Fig. 4A, lanes 1–3). Importantly, the TAPP
fraction further purified from AS Fr. I contained PP1c, but
not PP2Ac (Fig. 4A, lane 4). rPP1c and rPP2Ac were used
as positive controls (Fig. 4A, lanes 5 and 6, respectively).
Fractions were also analyzed for the presence of PP2C
by Western blotting (Fig. 4B). As shown in Fig. 4B (lanes
1–4), although the WCE, AS Fr. I, and AS Fr. II contained
PP2C, the TAPP fraction lacked PP2C. Thus, TAPP is
FIG. 3. TAPP is a type 1 protein phosphatase. Specific phosphatase
inhibitors were used to determine the type of phosphatase associated
with Tat. (A) Microcystin-LR and okadaic acid were used to determine
the IC50 for TAPP (circle), rPP1c (square), and rPP2Ac (triangle). (B)
Phosphatase inhibitors were added to the proteins associated with the
Tat affinity column at indicated concentrations before the addition of
the substrate, phosphorylase a. The dephosphorylation reactions were
analyzed by SDS–PAGE. Lane 1 shows the substrate, phosphorylated
phosphorylase a before phosphatase treatment, while lane 5 shows
phosphorylase a after incubation with TAPP (in the absence of inhibi-
tors). Lanes 2–4 show TAPP with 10 nM microcystein-LR (MC), 1 nM
okadaic acid (OA), and 200 nM OA, respectively. The phosphorylated
form of phosphorylase a is indicated.
FIG. 2. TAPP associates with the amino-terminus of Tat. (A) Activation
domain of Tat is sufficient for its association with Tat. AS Fr. I and II
were bound to either Tat48 or full-length Tat72 and were assayed for
phosphatase activity. Proteins that were bound to the GST-Tat column
were incubated with [32P]ATP-labeled phosphorylase a and the de-
phosphorylation reaction was performed and analyzed by 6% SDS–
PAGE. Lane 1 shows the substrate, phosphorylated phosphorylase a,
indicated by an arrow. Phosphatase activity is indicated by the disap-
pearance of radioactivity. (B) GST, GST-Tat72, GST-Tat48, and GST-VP16
affinity-purified phosphatase activity from AS Fr. I. The Tat-associated
proteins were incubated with phosphorylase a and phosphatase ac-
tivity was analyzed by scintillation counting as described under Mate-
rials and Methods. Results are the average of three measurements;
error bars represent the standard error of the mean (SEM). The asterisk
indicates a statistically significant difference (P  0.05).
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related to a serine/threonine, type 1 protein phosphatase
from human T cells.
PP1c associates with Tat in vivo
To determine if PP1c associated with Tat in vivo, nu-
clear extracts prepared from the HeLa-eTat cell line were
immunoprecipitated using an anti-HA antibody as previ-
ously described (Kashanchi et al., 2000). HeLa-eTat cells
express stably transfected HIV-1 Tat coding sequences,
which has hemagglutinin (HA) epitope tag at the car-
boxyl-terminus of Tat, while the HeLa-pCEP4 cells con-
tain the parental vector lacking HA-Tat coding se-
quences (Kashanchi et al., 2000). Western blot analysis
of the immunoprecipitated complexes using anti-PP1c
antibody indicated that PP1c associates with Tat (Fig. 5,
lane 1). Immunoprecipitation of the parental pCEP4 cell
extract using anti-12CA5 showed a lack of PP1c in the
immunocomplex (Fig. 5, lane 3). As a positive control for
proteins that associate with Tat, the P-TEFb/CDK9 was
assayed by Western blot analysis of the immunoprecipi-
tated complexes (Fig. 5, lane 1). When HeLa-eTat cell
extract was immunodepleted of HA-tagged Tat using
12CA5 antibody, PP1c could still be detected in the ex-
tract (not shown), indicating that a subset of the cellular
pool of PP1c associates with Tat.
TAPP dephosphorylates Serine 2 of CTDo
Next, we determined if the phosphorylated CTD was a
substrate for TAPP and if so, which serine residue was
the target. CDK9, which is part of TAK and P-TEFb, hy-
perphosphorylates CTD (CTDo) at serine 2 (Fig. 6, lane
1). In the presence of Tat on the other hand, CDK9
hyperphosphorylates both Ser 2 and Ser 5 residues in
CTD (Fig. 6, CTDo in lanes 7 and 10, respectively). We
asked if a specific serine residue of CTD was targeted by
TAPP-associated phosphatase. P-TEFb-associated CDK9
kinase was utilized to phosphorylate CTD in vitro, in
either the presence or the absence of Tat, and the hy-
perphosphorylated CTD was dephosphorylated in the
presence of TAPP or rPP1c as experimental controls.
Hyperphosphorylated CTD substrates phosphorylated
mainly at Ser 2, in the absence of Tat (top panels, Fig. 6),
or at both Ser 2 and Ser 5, in the presence of Tat (bottom
panels, Fig. 6), and were treated with TAPP or rPP1c
phosphatases. The reactions were resolved on SDS–
PAGE and transferred to PVDF and immunoblotted using
anti-H5 (Ser 2) and anti-H14 (Ser 5) antibodies. In agree-
ment with a published report (Zhou et al., 2000), in the
absence of Tat, CDK9 targets primarily the CTD Ser 2
residues for phosphorylation (Fig. 6, top panel, compare
the CTDo and CTDa bands in lanes 1 and 4). TAPP-
associated phosphatase activity targeted Ser 2 as ob-
served by a mobility shift from CTDo to CTDa (Fig. 6, top
panel, lane 2). In the presence of Tat, the substrate
specificity of CDK9 kinase is altered to include both Ser
FIG. 5. HA-Tat associates with PP1 in vivo. To demonstrate that Tat
associates with PP1c, in vivo, Tat was immunoprecipitated with anti-HA-
tag monoclonal antibody (12CA5) from 50 g HeLa-eTat cells (lane 1)
containing stably transfected HA-Tat, and from 50 g HeLa-pCEP4 cells
(lane 3) containing vector alone. Lane 2 represents recombinant PP1c
added as control. Position of rPP1c, 12CA5, and CDK9 is indicated.
FIG. 4. Analysis of TAPP by Western blot with anti-PP1c, anti-PP2Ac,
and anti-PP2Cc. WCE (lane 1), 0–40% AS Fr. I (lane 2), 40–100% AS Fr.
II (lane 3), and High Q fraction 24 (lane 4) were analyzed by Western
blotting. (A) Western blot analysis was performed using anti-PP1c and
anti-PP2Ac antibodies. Lane 5 shows rPP1c while lane 6 shows
rPP2Ac. (B) Western blot analysis using anti-PP2Cc. Lane 5 shows
rPP2Cc. Positions of PP1c (36 kDa) and PP2Ac (36 kDa) and PP2Cc (36
kDa) are indicated.
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2 and Ser 5 (Fig. 6, bottom panel, compare the CTDo
bands in lanes 7 and 10). TAPP dephosphorylated Ser 2
in the presence or absence of Tat (Fig. 6, lanes 2 and 8)
and was not able to dephosphorylate CTD at Ser 5 (Fig.
6, lane 11). Note that CTD Ser 2 site dephosphorylation
by TAPP is comparable to that of rPP1c in the absence or
presence of Tat (Fig. 6, lanes 3 and 9). Thus, the Tat-
associated protein phosphatase is unique in that it spe-
cifically targets the Ser 2 residues of CTDo for dephos-
phorylation. The identity of the “nonspecific” band
(marked with an asterisk in Fig. 6 lanes 10–12) is un-
known. The band appears only in the samples probed
with anti-H14 antibody, suggesting that it may be a deg-
radation product of CTD phosphorylated at Ser 5 in the
presence of Tat.
TAPP augments in vitro Tat transactivation from the
HIV-1 LTR
Having demonstrated that a serine/threonine protein
phosphatase type 1 specifically associates with HIV-1
Tat and that the hyperphosphorylated CTDo is a sub-
strate of the Tat-associated phosphatase, we asked
whether the target-specific dephosphorylation by TAPP
would be significant in Tat transactivation. Specifically
we asked if TAPP augmented the Tat-mediated transcrip-
tional transactivation of HIV-1 LTR in an in vitro transcrip-
tion reaction. Biotinylated HIV-1 LTR DNA templates
were utilized to purify preinitiation complexes from HeLa
nuclear extract. TAPP or rPP1c were added to the reac-
tion to asses their effect on transcription. Addition of the
TAPP fraction had little effect on the basal transcription,
whereas the Tat transactivation was markedly stimulated
with TAPP (Fig. 7A). Higher concentrations of TAPP down
regulated Tat transactivation (data not shown), suggest-
ing that an optimal response of the target-specific CTD
phosphatase may be necessary for Tat transactivation.
To ascertain that the effect on transcription stimulation
was due to the Tat-associated protein phosphatase, we
utilized the phosphatase inhibitor, okadaic acid. Our pre-
vious results suggested that 200 nM okadaic acid is
sufficient to inhibit PP1c (Fig. 3B). Okadaic acid (200 nM)
alone decreased the basal level of transcription (Fig. 7B,
lane 4), suggesting that HeLa nuclear extract contains
phosphatases that are important for basal transcription.
In addition, okadaic acid reversed the effects of TAPP on
both the basal and the Tat-induced transcription (Fig. 7B,
compare lanes 2 and 5, and 8 and 11), suggesting that
phosphatase is an important component of TAPP that is
required for Tat transactivation. The augmentation of Tat
transactivation with the addition of TAPP appears to be
similar to the induction with rPP1 (Fig. 7B, lanes 8 and 9),
suggesting that the TAPP-associated phosphatase activ-
ity is related to rPP1c.
To test the specificity of TAPP-mediated induction of
HIV-1 LTR, we asked whether TAPP affects transcription
of the Tax-responsive element (TRE) of the HTLV-1 LTR.
Biotinylated HTLV-1 TRE templates were incubated with
HeLa nuclear extract in the absence and presence of the
viral activator, Tax/CREB. The preinitiation complexes
were then purified with streptavidin-coated magnetic
beads. The in vitro transcription reactions were per-
formed with the purified PICs with or without Tax/CREB.
The result presented in Fig. 8 suggest that TAPP or rPP1c
had little effect on HTLV-1 TRE templates.
Preinitiation complexes assembled on HIV-1 LTR
contain PP1c
Having shown the role of PP1c in the Tat transactivation,
we asked whether PP1c is present in the preinitiation com-
plex assembled on the HIV-1 LTR. Immunoblot of HeLa
nuclear extract and of PICs assembled on the wild-type (wt)
LTR was performed using anti-PP1c, -PP2Ac, and -PP2Cc
antibodies. Figure 9 (lane 2) shows that HeLa nuclear
extract contains PP1c, PP2Ac, and PP2Cc. The PIC assem-
bled on to the anchored DNA template contained only PP1c
(Fig. 9, lanes 3 and 4), suggesting a unique role for PP1c in
the transcription initiation of HIV-1 LTR.
TAPP associates with HIV-1 LTR during transcription
initiation and dissociates during elongation
We next asked whether the TAPP-associated PP1c
assembled in the preinitiation complex remains with PIC
FIG. 6. TAPP dephosphorylates serine 2 of CTDo. TAPP was assayed
for CTD phosphatase activity. CTD was phosphorylated in vitro by
CDK9 and ATP in the absence of Tat (top panels) or the presence of Tat
(bottom panels). The dephosphorylation reactions were performed in
the presence of TAPP or rPP1c. Western blotting with anti-H5 (serine 2)
or anti-H14 (serine 5) monoclonal antibodies was performed. The
asterisk indicates nonspecific band. The two phosphorylated forms of
CTD are indicated by arrows.
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as a stable complex, or whether it exits the PIC at
specific stages of transcription elongation? To examine
the possibility, we performed a stepwise transcription
elongation assay and analyzed the presence of PP1c at
the various stages of elongation (Zhou et al., 2000).
Western blot analysis of stalled transcription complexes
demonstrates that PP1c is released from the transcrip-
tion complex between A22 and G36 (Fig. 10, lanes 4 and
5). To confirm that the transcription elongation reaction
was stable we analyzed other proteins associated with
the transcription complexes. CDK9 is present during
preinitiation as well as elongation (Fig. 10). Interestingly,
CDK9 associated with the transcription complex is grad-
ually phosphorylated when HIV-1 transcripts are elon-
gated beyond 22 nucleotides, the same point at which
TAPP exits the complex (Fig. 10, lanes 4–9). These re-
sults, therefore, argue that the phosphatase component
of TAPP associates with the HIV-1 promoter complex
during transcription initiation and dissociates during
transcript elongation. The release of TAPP-associated
PP1 activity from the elongating transcription complex
would suggest a significant temporal role of the Tat-
associated CTD Ser 2 phosphatase in viral gene trans-
activation, although its significance will be clearer with
the demonstration other specific substrates of TAPP.
DISCUSSION
Protein phosphorylation is an important posttransla-
tional modification event in eukaryotic cell metabolic
regulation (Hunter and Karin, 1992). The ability to co-
valently modify proteins by phosphorylation-dephosphor-
ylation gives eukaryotic protein kinases and phospha-
tases the unique role of regulating cellular functions
FIG. 7. TAPP augments Tat transactivation of the HIV-1 LTR. Biotinylated HIV-1 LTR templates were incubated with HeLa nuclear extract in the absence
or presence of Tat, and the preinitiation complexes (PICs) were then purified with strepavidin-coated magnetic beads. (A) The effect of added TAPP was
performed in the absence and presence of Tat in the transcription assays. (B) In vitro transcription reactions were performed with purified PICs, and the
addition of TAPP or rPP1c into transcription reactions is indicated in the figure. To test whether transcription was altered due to phosphatase activity, 200
nM okadaic acid was used in transcription reactions (lanes 4–6 and 10–12). The runoff transcripts are 168 nt as indicated in the figure.
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(Cohen, 1989). A number of studies suggest that tran-
script elongation is catalyzed by hyperphosphorylation of
RNAPII, whereas hypophosphorylated RNAPII preferen-
tially associates with preinitiation complexes. This im-
plies that the enzyme(s) involved in the conversion of
RNAPIIo to RNAPIIa may play a key role in transcriptional
regulation. While a number of cellular kinases that phos-
phorylate RNAPII have been identified and their role in
transcription elucidated, the role of protein phospha-
tases in transcription regulation has only been appreci-
ated more recently.
HIV-1 Tat transactivation serves as a useful model for
elucidating eukaryotic transcriptional elongation mecha-
nisms. Results described in this report demonstrate the
presence of TAPP, which is similar to PP1 activity that
specifically targets the Ser 2 residues of RNAPII CTD.
TAPP associates with Tat in vitro and in vivo, and, in
cell-free transcription assays, TAPP augments Tat trans-
activation of the HIV-1 LTR. Significantly, TAPP appears to
be associated with the HIV-1 promoter only during the
early stages of transcription elongation.
Since the hypophosphorylated form of CTD is known
to be associated with transcription initiation complex, it
is generally inferred that a specific phosphatase would
maintain a balance between the hypo- and hyperphos-
phorylated forms of RNAPII to sustain an efficient tran-
scription complex, such as the one tethered to HIV-1 LTR
by the Tat cofactors. Based on the results presented, we
would argue that TAPP would provide such a CTDo
phosphatase function. The results that PICs assembled
at the HIV-1 promoter contain functionally relevant PP1
(Fig. 9) would suggest an important role of the Tat-
associated phosphatase during the early stages of tran-
script elongation. Whether the orchestrated release of
TAPP from the transcription complexes has a direct role
in Tat-induced CDK9 activation (Zhou et al., 2001) is still
unclear.
It is generally agreed that the hypophosphorylated
form of RNAPII is associated with the PIC, whereas the
hyperphosphorylated form of RNAPII is associated with
the actively elongating complex (Dahmus, 1996). With
respect to HIV-1 LTR transcription, Tat is known to pri-
marily enhance transcriptional elongation efficiency.
However, other studies suggest that Tat induces tran-
scription during PIC formation, suggesting that Tat can
direct the assembly of a latent, elongation-competent
transcription complex during initiation (Liu et al., 1999).
The results presented here argue that the Tat-associated
FIG. 8. TAPP does not affect HTLV-1 transcription. Biotinylated
HTLV-1 LTR templates with HeLa nuclear extract in the absence and
presence of the viral activator, Tax/CREB. The 375 nt preinitiation
complexes (PICs) were then purified with streptavidin-coated magnetic
beads. The in vitro transcription reactions were performed with the
purified PICs. The addition of TAPP or rPP1c into HTLV-1 transcription
reactions is indicated in the figure.
FIG. 9. Preinitiation complexes assembled on HIV-1 LTR contain
PP1c. Preinitiation complexes (PICs) purified on biotinylated HIV-1 LTR
bound to streptavidin-coated magnetic beads were analyzed by immu-
noblotting using anti-PP1c, anti-PP2Ac, or anti-PP2Cc antibodies. Lane
1, rPP control. Lane 2, HeLa nuclear extract (HNE). PICs on the LTR
were analyzed for PPs in the absence or presence of Tat (lanes 3 and
4, respectively). Position of PP1c, PP2Ac, and PP2Cc (36 kDa) is
indicated.
FIG. 10. TAPP associates with HIV-1 LTR during transcription initia-
tion and dissociates during elongation. Lane 1 shows rPP1c. Preinitia-
tion complexes (PIC) were formed in the presence of TAPP. Elongation
to nucleotide 14, uracil (U14), proceeded with the addition of dATP, CTP,
GTP, and UTP and TAPP (lanes 3). Then stepwise addition of NTPs for
elongation from A15 to A22 (ATP, CTP, GTP); U23 to G26 (CTP, GTP,
UTP); A27 to C30 (ATP, CTP, GTP); U31 to G36 (ATP, GTP, UTP); C37 to
U46 (CTP, GTP, UTP); A47 to A51 (ATP, CTP, UTP); G52 to C61 (ATP, CTP,
GTP); U62 to U66 (CTP, GTP, UTP); A67 to G71 (ATP, CTP, GTP); and U72
to A79 (ATP, CTP, UTP) produced a transcript to A79. A, adenosine; U,
uracil; G, guanosine; and C, cytosine. Western blot analysis was per-
formed using anti-PP1c (top) and anti-CDK9 (bottom) antibodies.
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phosphatase, which appears to be an integral compo-
nent of the PIC complex formed on HIV-1 LTR, specifi-
cally induces Tat transactivation. Further studies will
elucidate whether the temporal association of the Tat-
associated phosphatase, its unique property of specifi-
cally dephosphorylating the CTD Ser 2 residues, and its
orchestrated release from the transcription complex
once elongation commences, defines the Tat-induced
processive elongation of viral transcripts.
Even though the in vitro transcription assays per-
formed in this study do not support multiple rounds of
transcription by RNAPII, the results suggest that TAPP
may function to dephosphorylate hyperphosphorylated
forms of RNAPII in HeLa nuclear extract (HNE). Conver-
sion of RNAPIIo to RNAPIIa by TAPP ensures entry of
RNAPII into the preinitiation complexes. Since TAPP is
incubated with HNE prior to the transcription reaction, it
is possible that the dephosphorylation of RNAPIIo by
TAPP is a prerequisite for RNAPIIa to enter into preini-
tiation complexes.
An issue of particular interest is the Tat-specific mod-
ification of P-TEFb that alters a general transcription
elongation factor into one uniquely suited to processive
transcription of HIV-1 promoter. Based on the target-
specific phosphorylation of the CTD residues, it is clear
from a number of studies (Garber et al., 2000; Zhou et al.,
2000), that the defining phenotype of Tat response is the
switch from Ser 2 to Ser 5 phosphorylation. The results
presented here would argue that TAPP-mediated de-
phosphorylation of the CTD Ser 2 residues early in tran-
scription elongation may facilitate this unique Tat re-
sponse (predominantly CTD Ser 5 phosphorylated resi-
dues; Zhou et al., 2001). Although the phosphorylation of
both serine 2 and 5 sites of RNAPII CTD has been
suggested as being essential in transcription reactions,
the role of specific CTD phosphorylation sites has not
been fully resolved. TAPP may play an important role in
Tat transactivation by dephosphorylating serine 2 resi-
dues of CTD of RNAPII during initiation, prior to CTD
phosphorylation and transcription elongation by the Tat/
P-TEFb complex. We suggest that the Tat-associated
protein phosphatase may provide a unique role in the
PIC by maintaining an adequate balance of CTD Ser 2
site phosphorylation until the stage in HIV-1 LTR tran-
script elongation when Tat-specific CDK9 activation is
complete, and the CTD Ser 5 residues are preferentially
phosphorylated (Zhou et al., 2001). Further studies are
required to demonstrate a direct role of TAPP in modu-
lating specific steps of HIV-1 transcriptional transactiva-
tion. A plausible model would predict that the TAPP
activity maintains CDK9 kinase in the preelongation
state, whereas an as yet unidentified CDK9 kinase, or
CDK9 autophosphorylation, constitutes the transcript
elongation phase (Garber et al., 2000; Zhou et al., 2001).
MATERIALS AND METHODS
Cell culture
Human Jurkat T cells were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated fetal
bovine serum, 2 mM glutamine, and 1% penicillin/strep-
tomycin at 37°C in a 5% CO2 atmosphere. For protein
purification, large volumes of Jurkat cell culture were
purchased from the Cell Culture Center (Minneapolis,
MN) at the National Center for Research Resources,
sponsored by the National Institutes of Health.
Bacterial expression of fusion proteins
Glutathione S-transferase (GST) fusion proteins of
Tat72, Tat48, VP16, and CTD were expressed in Esche-
richia coli and purified on glutathione-agarose beads as
previously described (Kashanchi et al., 1996). GST-Tat72
and GST-Tat48 were obtained from NIH repository and
GST-VP16 was purified by Andy Rice. GST-CTD was a
generous gift of Richard Gaynor and was expressed as
described (Peterson et al., 1992).
Purification of TAPP
Whole cell extract from Jurkat cells was prepared by
the Manley protocol as described (Manley et al., 1980).
The extract was then partially purified by ammonium
sulfate precipitation at 0–40% saturation (Fraction I) fol-
lowed by 40–100% saturation (Fraction II). Proteins pre-
cipitated at the two salt concentrations were collected by
centrifugation, resuspended in Manley buffer (20 mM
HEPES, pH 7.9, 50 mM KCl, 12.5 mM MgCl2, 0.1 mM
EDTA, 10% glycerol, 0.1 mM PMSF, 2 mM DTT), and
dialyzed against Manley buffer (50 mM KCl).
Ammonium sulfate Fraction I-enriched phosphatase
activity was refractionated by loading onto a High Q
anion-exchange column (Bio-Rad) equilibrated with 50
mM Manley buffer. The column was eluted with 8 vol of
a linear gradient of 0.05 to 0.750 M KCl.
The Tat-associated proteins were purified as de-
scribed in Nekhai et al. (1997). AS Fr. I or column frac-
tions were incubated with 1–2 g GST-Tat fusion protein
bound to glutathione-agarose beads in 100 l reaction
volume with Manley buffer described above. The beads
were washed 4–5 times with Manley buffer to remove
nonspecific proteins and the phosphatase activity was
analyzed using either phosphorylase a or GST-CTD as
the substrate.
Phosphorylase a assay
The Tat-associated phosphatase activity was assayed
using [-32P]ATP-labeled phosphorylase a. Phosphory-
lase a was prepared by phosphorylating 12.5 mg/ml
phosphorylase b (Calzyme) using 0.2 mg/ml phosphory-
lase kinase (Sigma) in the presence of a buffer contain-
ing 8 pmol [32P]ATP, 50 nM ATP, 125 M CaCl2, 3 mM
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MgOAc, 50 mM Tris, pH 8.0, and 50 mM glycerophos-
phate as previously described (Shenolikar and Ingebrit-
sen, 1984; Cohen et al., 1988). Tat-associated proteins
(50 l) were incubated with phosphorylated phosphory-
lase a for 10 min at 30°C. The reactions were stopped
with SDS sample buffer and analyzed by 10% SDS–PAGE.
The phosphatase reactions were terminated by the ad-
dition of 10% (w/v) trichloroacetic acid (TCA; 0.1 ml). The
suspension was allowed to stand for 2 min at ambient
temperature and centrifuged for 2 min at 13,000 g. An
aliquot of the supernatant (0.12 ml) was removed and
mixed with 1.0 ml of dioxane-based scintillant for deter-
mining the radioactivity.
Phosphatase inhibitor assay
GST-Tat-associated proteins were incubated with
phosphatase inhibitors, microcystin-LR (10 nM; Sigma)
and okadaic acid (200 nM and 1 nM) (Upstate Biotech-
nology) (Hamm-Alvarez et al., 1996), for 10 min at 30°C
followed by the addition of the phosphorylase a sub-
strate and further incubation for 10 min and analyzed by
10% SDS–PAGE as above.
Epitope-tagged Tat-expressing cell extract
HeLa CD4 cells were transfected with either an
epitope-tagged (influenza HA epitope at the C-terminus
of Tat1–86) plasmid or the parental vector pCEP4 as
previously described (Kashanchi et al., 2000), and the
stably transfected cells were selected under 200 g
hygromycin/ml. Dignam nuclear extracts were prepared
as described (Dignam et al., 1983) and used in immuno-
precipitation assays described below.
Immunoprecipitation assays
Immunoprecipitations (IPs) were performed as de-
scribed previously (Kashanchi et al., 1996). Cellular pro-
tein (50 g) was mixed with monoclonal antibody (1.0 g)
for 2 h at 4°C. Protein A-Sepharose (5 l; Amersham-
Pharmacia) beads were added and incubated for an
additional 2 h. The immunoprecipitated complex was
then spun down and washed with Manley buffer contain-
ing 500 mM KCl (three times; 1 ml each) followed by 3
washes with Manley buffer containing 50 mM KCl. IPs
using anti-CDK9 were used in CTD kinase assays (see
below) and IPs using anti-12CA5 were used in Western
blot analysis using anti-PP1c, anti-12CA5, and anti-CDK9
antibodies.
Phosphorylation of serine 2 and serine 5 in CTD
Recombinant GST-CTD was phosphorylated in vitro
with CDK9 immunoprecipitated from HeLa nuclear ex-
tract in either the presence or the absence of Tat (see
below). The reaction was stopped by adding EDTA up to
7 mM and then TAPP or rPP1 was added for 30 min at
30°C. The reactions were resolved by SDS–PAGE and
transferred to a PVDF membrane and the presence of
phosphorylated serine 2 and serine 5 was detected by
immunoblotting using monoclonal antibodies specific to
phosphorylated serine 2 (anti-H4) or phosphorylated
serine 5 (anti-H14) residues.
In vitro transcription assay with HIV-1 promoter
The HIV-1 LTR template (nt 110 to 168) was biotinyl-
ated at the 5 end by using biotinylated primers during PCR.
Biotinylated LTR templates were incubated with HeLa nu-
clear extract to isolate preinitiation complexes during in
vitro transcription (IVT). Transcription reactions (50 l) con-
tained 25 l of HeLa nuclear extract, 1.0 g of biotinylated
HIV-1 LTR template, 1.0 g of poly(dI-dC), purified Tat pro-
tein in 1X IVT buffer (50 mM KCl, 6.25 mM MgCl2, 20 mM
HEPES, pH 7.9, 2 mM DTT, 0.5 mM EDTA, pH 8.0, 10 M
ZnSO4, 10 mM creatine phosphate, 100 g/ml creatine
kinase, and 8.5% glycerol). After a 30-min incubation at
30°C, streptavidin-coated magnetic beads (Dynabeads, Dy-
nal) preequilibrated in binding buffer (20 mM HEPES, pH
7.9, 80 mM KCl, 10 mM MgCl2, 2 mM DTT, 10 M ZnSO4,
100g/ml BSA, 0.05% NP-40, and 10% glycerol) were added
to the reaction mixture. The transcription mixes were then
incubated for an additional 30 min. Preinitiation complexes
assembled on biotinylated templates were enriched using
a magnetic stand and washed extensively with 1X IVT
buffer. In vitro transcription and Western blot analysis were
performed using the purified preinitiation complexes as-
sembled on the immobilized templates.
IVT reactions (100 l) were set up by resuspending the
purified PICs in 100 l IVT buffer, 50 M ATP, 50 M CTP,
50 M GTP, 10 Ci [-32P]UTP, and 10 units of RNAsin
(Promega). TAPP, rPP1c, and okadaic acid were added to
selected reactions. The IVT mixtures were incubated for
60 min at 30°C. RNA transcripts were purified and frac-
tionated by electrophoresis on a 7 M urea/6% TBE gel.
In vitro transcription assay with HTLV-1 promoter
The 375 nt G-free HTLV-1 LTR templates were biotin-
ylated at the 5 end. Biotinylated HTLV-1 LTR templates
were incubated with HeLa nuclear extract in the absence
and presence of the viral activator, Tax/CREB. The preini-
tiation complexes were then purified with streptavidin-
coated magnetic beads. The in vitro transcription reac-
tions were performed with the purified PICs. The addition
of TAPP or rPP1c into HTLV-1 transcription reactions is
indicated in the figure.
Stepwise transcription elongation
The purified PICs were incubated with 50 M ATP for
10 min and then washed extensively with 1X IVT buffer.
The PICs were walked to position U14 by incubation with
50 M CTP, GTP, and UTP for 5 min at 30°C and then
washed extensively with 1X IVT buffer. The transcrip-
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tional elongation complexes (TECs) stalled at U14 were
walked stepwise along the DNA by repeated incubation
with different sets of three NTPs and then washed ex-
tensively with 1X IVT buffer to remove the unincorporated
NTPs. To analyze the components of TECs, the TECs
were elongated with cold NTPs. The TECs stalled at
different stages were analyzed by Western blot.
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